Hengist · Cell reports. Medicine 2024 · randomized controlled trial · n=?

Ketogenic diet but not free-sugar restriction alters glucose tolerance, lipid metabolism, peripheral tissue phenotype, and gut microbiome: RCT.

Cited 44 times in the scientific literature.

Level 2 - randomized trial

Individual randomized controlled trial in humans

PubMed 39106867 · doi:10.1016/j.xcrm.2024.101667 · record verified 2026-08-27

What was done

Healthy adults were randomized to a 12-week intervention involving free-sugar restriction, overall carbohydrate restriction (ketogenic diet), or a control diet. Investigators measured changes in body fat mass, energy expenditure, glucose tolerance, lipid and inflammatory markers (LDL-C, apolipoprotein B, C-reactive protein, postprandial glycerol), skeletal muscle signaling markers (PDK4, AMPK, GLUT4), and gut microbial beta diversity across 4 and 12 weeks.

What was found

The abstract reports directions of effect without numerical values or confidence intervals. Both dietary interventions reduced fat mass without altering energy expenditure compared with controls. Free-sugar restriction decreased LDL-C with minimal impact on other metabolic markers or the gut microbiome. The ketogenic diet reduced glucose tolerance, increased muscle PDK4, and decreased muscle AMPK and GLUT4. At week 4, the ketogenic diet decreased fasting glucose and increased apolipoprotein B, C-reactive protein, and postprandial glycerol; these specific week-4 changes were no longer evident by week 12 despite sustained ketosis. At week 12, the ketogenic diet significantly altered gut microbial beta diversity.

Why it matters

These findings show that while both sugar restriction and ketogenic diets can achieve fat loss without slowing energy expenditure, they have divergent physiological effects, with the ketogenic diet inducing acute reductions in glucose tolerance and changes in gut microbiome composition not seen with free-sugar restriction alone.

Limits

The abstract does not disclose the sample size, participant demographics, dietary compliance metrics, or numerical effect sizes. The 12-week duration in healthy adults limits conclusions regarding long-term clinical safety, durability, or generalizability to populations with baseline metabolic disorders.

Cited by